Kintegral Advisory LLC Sells 803 Shares of Agilent Technologies, Inc. (NYSE:A)

Kintegral Advisory LLC decreased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 4.4% in the 4th quarter, HoldingsChannel reports. The fund owned 17,243 shares of the medical research company’s stock after selling 803 shares during the period. Kintegral Advisory LLC’s holdings in Agilent Technologies were worth $2,321,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Van ECK Associates Corp lifted its position in Agilent Technologies by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock valued at $442,011,000 after acquiring an additional 183,716 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Agilent Technologies in the third quarter worth approximately $14,848,000. Empowered Funds LLC lifted its holdings in shares of Agilent Technologies by 29.8% in the third quarter. Empowered Funds LLC now owns 30,978 shares of the medical research company’s stock valued at $4,592,000 after purchasing an additional 7,111 shares in the last quarter. S.E.E.D. Planning Group LLC boosted its position in shares of Agilent Technologies by 12.7% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock valued at $5,721,000 after buying an additional 4,805 shares during the last quarter. Finally, National Pension Service grew its holdings in Agilent Technologies by 10.8% during the third quarter. National Pension Service now owns 702,631 shares of the medical research company’s stock worth $104,327,000 after buying an additional 68,670 shares in the last quarter.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Wall Street Analyst Weigh In

A has been the topic of several recent analyst reports. Bank of America dropped their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Citigroup upped their price objective on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Finally, Sanford C. Bernstein reduced their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a report on Tuesday, November 26th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $144.38.

Agilent Technologies Stock Performance

NYSE:A opened at $135.33 on Friday. The company has a market capitalization of $38.61 billion, a P/E ratio of 30.62, a P/E/G ratio of 3.67 and a beta of 1.07. The business has a fifty day simple moving average of $140.97 and a two-hundred day simple moving average of $139.31. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. Agilent Technologies, Inc. has a 1 year low of $124.16 and a 1 year high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.38 EPS. On average, analysts expect that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s payout ratio is currently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.